Table 3 Subgroup analyses of recurrence and tumor response.

From: Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis

Subgroup

No. of studies

No. of patients

Estimates (HR/OR)

Lower limit to upper limit

P‐value

DFS/RFS

Hepatectomy

12

3155

1.70

1.51–1.92

 < 0.001

LDLT

3

295

4.13

2.14–7.97

 < 0.001

ORR

Systemic therapy

4

396

0.21

0.09–0.46

 < 0.001

TACE

2

265

0.70

0.28–1.72

0.434

DCR

Systemic therapy

4

396

0.52

0.34–0.82

0.004

TACE

2

265

0.55

0.10–3.06

0.500

  1. LDLT Living-Donor Liver Transplantation, TACE transarterial chemoembolization, DFS disease-free survival, RFS recurrence-free survival, ORR objective response rate, DCR disease control rates.
Back to article page